PT  - JOURNAL ARTICLE
AU  - D.J. Smith
AU  - S.T. Yerkovich
AU  - M.A. Towers
AU  - M.L. Carroll
AU  - R. Thomas
AU  - J.W. Upham
TI  - Reduced soluble receptor for advanced glycation end products in chronic obstructive pulmonary disease
AID  - 10.1183/09031936.00029310
DP  - 2010 Jan 01
TA  - European Respiratory Journal
PG  - erj00293-2010
4099  - http://erj.ersjournals.com/content/early/2010/07/01/09031936.00029310.short
4100  - http://erj.ersjournals.com/content/early/2010/07/01/09031936.00029310.full
AB  - The soluble receptor for advanced glycation end-products (sRAGE) has anti-inflammatory properties, and deficiency of circulating sRAGE is associated with various human diseases. Whether sRAGE concentrations are reduced in COPD has not been determined. The aim of this study was to determine plasma levels of sRAGE in COPD patients and establish whether sRAGE varies in relation to FEV1 and other inflammatory markers.61 COPD patients and 42 healthy controls were recruited. Plasma sRAGE, C-reactive protein (CRP) and serum amyloid A (SAA) were measured in patients with stable COPD. A sub-group had measurements during acute exacerbations of COPD (AECOPD).sRAGE was significantly lower in stable COPD than in healthy controls (p<0.001), while CRP (p<0.001) and SAA (p=0.015) were higher in stable COPD than in healthy controls. Multiple linear regression confirmed that COPD was negatively associated with sRAGE (p<0.001). Plasma sRAGE was positively correlated with FEV1 (r2=0.530, p<0.001), while CRP and SAA were inversely proportional to FEV1. Multiple linear regression analysis showed that only sRAGE was a strong predictor of FEV1. AECOPD were associated with even lower sRAGE levels that increased with convalescence.Circulating sRAGE is lower in COPD and shows a strong correlation to the degree of airflow limitation.